USPTO Examiner SCHLIENTZ LEAH H - Art Unit 1618

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18629717MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOFApril 2024June 2025Allow1410NoNo
18436484CARBONIC ANHYDRASE IX TARGETING AGENTS AND METHODSFebruary 2024June 2025Abandon1701NoNo
18428432NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOFJanuary 2024June 2025Abandon1610NoNo
18571259ORAL CARE COMPOSITION, AND PREPARATION METHOD AND APPLICATION THEREOFDecember 2023August 2024Allow810NoNo
18548546COMPOUND TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN, AND PREPARATION METHOD AND APPLICATION THEREOFAugust 2023December 2023Allow400NoNo
18349833METHODS AND COMPOSITIONS FOR VISUALIZING A URETER IN A SURGICAL PROCEDUREJuly 2023July 2024Allow1220YesNo
18137721Nanoparticle Photoacoustic Imaging AgentsApril 2023May 2025Abandon2511NoNo
18108464ENCAPSULATION OF MICROBUBBLES WITHIN THE AQUEOUS CORE OF MICROCAPSULESFebruary 2023May 2025Abandon2710NoNo
18163000TARGETING LIGANDS FOR TAU PATHOLOGYFebruary 2023December 2024Allow2210NoNo
18100953Bismuth-Gadolinium NanoparticlesJanuary 2023April 2025Allow2720NoNo
18081916POLYDOPAMINE DECORATED TOBACCO MOSAIC THERANOSTIC VIRUS NANOPARTICLESDecember 2022November 2024Allow2310NoNo
17990347FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETONovember 2022March 2025Abandon2820NoNo
18055100FUNCTIONALIZED LIPOSOMES FOR IMAGING MISFOLDED PROTEINSNovember 2022June 2025Abandon3120NoNo
18049288PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCEROctober 2022June 2024Abandon1910NoNo
17892203PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCERAugust 2022May 2024Abandon2010NoNo
17809810FIBROBLAST ACTIVATION PROTEIN (FAP) TARGETED IMAGING AND THERAPY IN FIBROSISJune 2022November 2023Allow1620NoNo
17847194PARTICLES FOR USE IN HYPERPOLARIZATIONJune 2022April 2025Allow3331NoNo
17842418NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOFJune 2022February 2024Abandon2010NoNo
17830165LIPID MICROBUBBLES AND PROCESS OF MAKING THEREOFJune 2022June 2024Allow2420YesNo
17827560SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONSMay 2022January 2024Abandon2010NoNo
17744128COMPOSITIONS COMPRISING HYPERPOLARIZED PROBES FOR H2O2 SENSING AND METHODS OF USING SAMEMay 2022May 2025Allow3600NoNo
17662574SILICONE-BASED DYES WITH SHORT WAVELENGTH INFRARED ABSORPTION AND EMISSION AND METHODS FOR MAKING AND USING THE SAMEMay 2022February 2025Allow3421NoNo
17739031TARGETING LIGANDS FOR TAU PATHOLOGYMay 2022November 2022Allow610YesNo
17736957LOW X-RAY ATTENUATION CHANGE HARD SHELLED ORAL CONTRAST MATERIALMay 2022June 2025Abandon3730NoNo
17714251TARGETED NANO-PHOTOMEDICINES FOR PHOTODYNAMIC THERAPY OF CANCERApril 2022June 2024Abandon2710NoNo
17657028SURFACTANT MICROBUBBLES AND PROCESS FOR PREPARING AND METHODS OF USING THE SAMEMarch 2022September 2024Abandon3011NoNo
17686962RAPIDLY DISINTEGRATING GELATINOUS COATED TABLETSMarch 2022January 2024Abandon2210NoNo
17652037COMPOSITIONS AND METHODS FOR ASSESSING GUT FUNCTIONFebruary 2022April 2024Allow2520NoNo
17552984Macrocyclic Agents for Targeted Dual-Modality PET and MRI Imaging of CancerDecember 2021December 2023Abandon2310NoNo
17523911Novel Contrast Agents and Imaging Methods for Early Detection of DiseasesNovember 2021November 2023Abandon2401NoNo
17497119MAGNETIC TRACER COMPOSITIONSOctober 2021August 2023Allow2240NoNo
17403058TARGETED CONTRAST AGENTS FOR MRI OF AMYLOID DEPOSITIONAugust 2021May 2025Abandon4520NoNo
17368272REAGENT FOR BIOCONJUGATION VIA IRREVERSIBLE REBRIDGING OF DISULFIDE LINKAGESJuly 2021October 2023Abandon2710NoNo
17352773TARGETED GAS-FILLED MICROVESICLES FORMULATIONJune 2021April 2024Allow3420NoNo
17311299FLUOROUS METAL CHELATES COMPOSITIONSJune 2021January 2025Allow4411YesNo
17319912VEGETABLE OIL-DERIVED CONTRAST AGENT WITH HIGH STABILITY AND PREPARATION METHOD THEREOFMay 2021June 2024Allow3740NoNo
17293176BISMUTH METAL-ORGANIC FRAMEWORKS FOR USE AS X-RAY COMPUTED TOMOGRAPHY CONTRAST AGENTSMay 2021December 2023Abandon3110NoNo
17245938RADIOFLUORINATED GPC3-BINDING PEPTIDES FOR PET IMAGING OF HEPATOCELLULAR CARCINOMAApril 2021November 2023Abandon3011NoNo
17234323BI-DOTA COMPLEX-LOADED DENDRITIC POLYMER NANOPARTICLESApril 2021August 2024Allow4021NoNo
17285717FIBROBLAST ACTIVATION PROTEIN (FAP) TARGETED IMAGING AND THERAPY IN FIBROSISApril 2021March 2022Allow1100NoNo
17224492MOLECULAR SENSORS WITH MODIFIED LIGANDSApril 2021January 2025Abandon4621NoNo
17211481FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETOMarch 2021February 2023Allow2311NoNo
17204524NANOPARTICLE-ALGINATE GELS FOR X-RAY IMAGING OF THE VASCULATUREMarch 2021January 2023Allow2320YesNo
17275978Alpha Emitter Compositions And MethodsMarch 2021November 2024Allow4431NoNo
17196036COMPOSITIONS AND METHODS FOR DRUG DELIVERYMarch 2021May 2024Abandon3811NoNo
17191713COMPOSITION FOR CROSS TALK BETWEEN ESTROGEN RECEPTORS AND CANNABINOID RECEPTORSMarch 2021September 2024Abandon4210NoNo
17272636COMPOSITION FOR DETECTING HYDROGEN SULFIDE OR MEASURING HYDROGEN SULFIDE CONCENTRATION AND COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR DIAGNOSING OR IMAGING IN VIVO INFLAMMATION, TISSUES HAVING HYPOXIC DAMAGE, OR CANCERMarch 2021March 2025Allow4820YesNo
17169455PLATINUM SULFIDE PROTEIN NANOPARTICLE HAVING NEAR-INFRARED PHOTOTHERMAL EFFECT AND MULTI-MODAL IMAGING FUNCTION, PREPARATION METHOD THEREFOR AND APPLICATION THEREOFFebruary 2021May 2022Allow1510NoNo
17265850METHOD FOR DIAGNOSIS OF DOPAMINERGIC AND MOVEMENT DISORDERSFebruary 2021October 2022Abandon2110NoNo
17162126TARGETED CONTRAST AGENTS FOR MRI OF AMYLOID DEPOSITIONJanuary 2021May 2021Allow310YesNo
17158332Affinity Magnetic Particles For Imaging SystemJanuary 2021July 2023Abandon3021NoNo
17248340AGGREGATION-INDUCED EMISSION LUMINOGENS FOR PHOTODYNAMIC THERAPYJanuary 2021September 2023Allow3231NoNo
17150488FLUORESCENCE IMAGING METHOD AND SYSTEMJanuary 2021April 2023Abandon2711NoNo
17257387REAGENT AND PROCESS FOR THE SITE-SPECIFIC DEOXYFLUORINATION OF PEPTIDESDecember 2020September 2024Abandon4411NoNo
17129490POLYDOPAMINE DECORATED TOBACCO MOSAIC THERANOSTIC VIRUS NANOPARTICLESDecember 2020July 2022Allow1910NoNo
17126340MRI CONTRAST AGENT INCLUDING T1 CONTRAST MATERIAL COATED ON SURFACE OF NANOPARTICLE SUPPORTDecember 2020February 2025Allow5031YesNo
17252100EMULSION FOR ULTRASOUND ABLATION SURGERYDecember 2020November 2024Allow4731NoNo
17251786Composition Containing a Somatostatin Analogue for Radiopharmaceutical UseDecember 2020February 2025Allow5020YesNo
17111953CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGINGDecember 2020April 2024Abandon4121NoNo
17104859DYE AGGREGATES-CONTAINING NANOPARTICLES AND USES THEREOFNovember 2020December 2023Abandon3721NoNo
17103366PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCERNovember 2020September 2023Abandon3410NoNo
17093155Ultrasound Gel CompositionNovember 2020September 2023Abandon3410NoNo
17053702BIO-BASED MATERIAL WITH ANTIBACTERIAL EFFECT AND USE THEREOFNovember 2020May 2025Allow5440YesNo
17050897VITAMIN E DERIVATIVES AND THEIR USE AS MULTI-SCALE IMAGING AGENTSOctober 2020November 2022Abandon2520NoNo
17050121Intranasal Delivery of Fluorescent MarkerOctober 2020October 2024Abandon4821NoNo
17046385NOBLE METAL-COATED MECHANORESPONSIVE VESICLESOctober 2020December 2024Abandon5030NoYes
17065319COLOR-CODED AND SIZED LOADABLE POLYMERIC PARTICLES FOR THERAPEUTIC AND/OR DIAGNOSTIC APPLICATIONS AND METHODS OFPREPARING AND USING THE SAMEOctober 2020April 2022Allow1910YesNo
17060059PH and Oxygen dual-sensitive magnetic resonance imaging contrast agent and preparation method thereofSeptember 2020May 2022Abandon1930NoNo
17042408PYCLEN-BASED MACROCYCLIC LIGANDS, CHELATES THEREOF AND USES THEREOFSeptember 2020June 2024Allow4441YesNo
16982856NOVEL COMPOUND, ANTIINFLAMMATORY DRUG COMPRISING THE COMPOUND AND CYCLOOXYGENASE-2 INHIBITOR COMPRISING THE COMPOUNDSeptember 2020March 2024Allow4240NoNo
16979017MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOFSeptember 2020November 2023Allow3831NoNo
16491866CONTRAST MEDIUM FOR MICROANGIOGRAPHYSeptember 2020February 2024Abandon5420NoNo
16978344PREPARATION OF SIZE-CONTROLLED MICROVESICLESSeptember 2020May 2023Allow3330YesNo
16971545METHOD FOR PRODUCING LUMINESCENT PARTICLES, LUMINESCENT PARTICLES, AND BIOIMAGING MATERIALAugust 2020March 2024Allow4341YesNo
16991404ENHANCED SN-38 ANTICANCER AGENTAugust 2020June 2021Allow1010NoNo
16968766TARGETED MICROBUBBLE, PREPARATION METHOD THEREOF, AND USE THEREOFAugust 2020April 2023Abandon3201NoNo
16987277PROBES FOR IMAGING HUNTINGTIN PROTEINAugust 2020January 2022Allow1710NoNo
16943326Metal Oxide Nanoparticle-Based Magnetic Resonance Imaging Contrast Agent with a Central CavityJuly 2020January 2022Allow1810NoNo
16940601CONTRAST IMAGING AGENT WITH DISSOLVED GAS-EVOLVING FLUIDJuly 2020October 2022Allow2711NoNo
16964323NON-METALLIC MAGNETIC RESONANCE CONTRAST AGENTJuly 2020May 2023Allow3411NoNo
16935998MICROBUBBLE TETHER FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONSJuly 2020January 2021Allow610NoNo
1693441468Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTSJuly 2020April 2023Abandon3320NoNo
16933198Metal Oxide Nanoparticle-Based T1-T2 Dual-Mode Magnetic Resonance Imaging Contrast AgentJuly 2020August 2021Allow1310NoNo
16922762TARGETING LIGANDS FOR TAU PATHOLOGYJuly 2020October 2022Abandon2701NoNo
16916817CONTRAST AGENTSJune 2020April 2021Allow910NoNo
16956995ANIONIC CHELATE COMPOUNDSJune 2020May 2021Allow1120YesNo
16771696NEW DAZA CHELATORS AS LIGANDS IN LIVER IMAGINGJune 2020February 2023Allow3220YesNo
16887974Encapsulation of Microbubbles Within the Aqueous Core of MicrocapsulesMay 2020March 2022Allow2210YesNo
16867685TARGETED GAS-FILLED MICROVESICLES FORMULATIONMay 2020March 2021Allow1010YesNo
16761473Metal Nanoparticles and Methods of Making SameMay 2020April 2024Allow4831YesNo
16855547POSITIVELY CHARGED NANOPARTICLES, USE THEREOF, AND PREPARATION METHOD THEREOFApril 2020May 2024Allow4840YesNo
16851585Macrocyclic Agents for Targeted Dual-Modality PET and MRI Imaging of CancerApril 2020January 2022Abandon2030NoNo
16756433SYSTEM AND METHOD TO PROVIDE A CONTRAST AGENTApril 2020November 2024Allow5541YesNo
16753875METHODS AND SYSTEMS FOR PRODUCING, USING, AND ADMINISTERING HYPERPOLARIZED FLUIDSApril 2020October 2024Allow5441NoNo
16834871Ultrasound Gel CompositionMarch 2020December 2020Abandon810NoNo
16829498METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLSMarch 2020October 2022Allow3111NoNo
16823058RAPIDLY DISINTEGRATING GELATINOUS COATED TABLETSMarch 2020February 2022Allow2330NoNo
16646549HYPERPOLARIZED AND DEUTERIUM EXCHANGED HYPERPOLARIZED13C AND 15N-LABELED XANTHINE, ARGININE, GLUTAMINE, AND UREA PROBESMarch 2020January 2022Allow2220YesNo
16641773HyperPolarising Substrates Through Relayed Transfer Via Systems Containing Exchangeable ProtonsFebruary 2020June 2023Abandon4020NoNo
16638066MAGNETIC STRUCTURESFebruary 2020November 2024Abandon5731NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SCHLIENTZ, LEAH H.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
14
Examiner Affirmed
12
(85.7%)
Examiner Reversed
2
(14.3%)
Reversal Percentile
24.3%
Lower than average

What This Means

With a 14.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
63
Allowed After Appeal Filing
5
(7.9%)
Not Allowed After Appeal Filing
58
(92.1%)
Filing Benefit Percentile
10.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 7.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SCHLIENTZ, LEAH H - Prosecution Strategy Guide

Executive Summary

Examiner SCHLIENTZ, LEAH H works in Art Unit 1618 and has examined 623 patent applications in our dataset. With an allowance rate of 42.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner SCHLIENTZ, LEAH H's allowance rate of 42.1% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SCHLIENTZ, LEAH H receive 2.42 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SCHLIENTZ, LEAH H is 46 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +43.1% benefit to allowance rate for applications examined by SCHLIENTZ, LEAH H. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 16.7% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 28.3% of cases where such amendments are filed. This entry rate is in the 32% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 60.0% of appeals filed. This is in the 29% percentile among all examiners. Of these withdrawals, 71.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 74.8% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.0% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.